In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...
This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial . KT-621 BROADEN2 Phase 2b AD trial ongoing, with data e ...
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback